



CAMSON BIO TECHNOLOGIES LIMITED

August 11th, 2016
Bangalore

To
The Listing Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 538858

Dear Sir

Sub: Outcome of Board Meeting dated August 11, 2016

As informed vide our letter dated August 4th, 2016, the Board of Directors of Camson Bio Technologies Limited, Bangalore met today and *inter-alia* transacted the following business:

1. Considered and approved the Unaudited Financial Results on standalone basis for the Quarter ended June 30, 2016 and the said results are enclosed herewith along with Limited Review Report.
2. Considered and approved Board's Report and other Annual General Meeting related matters.

The meeting commenced at 4.00 P.M. and concluded at 5.00 P.M.

Kindly take the same on record.

Please treat this as compliance with the Listing Agreement and SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Thanking You

For Camson Bio Technologies Limited


Sunil Puri
Director
DIN: 07509682



Encl: a/a

CAMSON BIO TECHNOLOGIES LIMITED
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016

Rupees in Lakhs

Sl. No.	Particulars	Standalone			
		Quarter Ended			Previous Year Ended
		30th June 2016	31st March 2016	30th June 2015	31st March 2016
		(Unaudited)	Refer Note 6	(Unaudited)	Refer Note 6
1	Income from Operations				
	(a) Net sales / income from Operations (Net of Excise duty)	205.05	(563.45)	1,861.86	2,540.33
	(b) Other Operating Income	-	-	-	-
	Total income from Operations (net)	205.05	(563.45)	1,861.86	2,540.33
2	Expenses				
	(a) Cost of Materials consumed	19.43	32.50	191.06	574.81
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	74.10	121.27	122.08	(91.23)
	(d) Employee benefits expenses	156.77	170.60	335.57	992.40
	(e) Depreciation and amortisation expenses	187.20	1,385.93	308.44	2,171.77
	(f) Other expenses (Any Item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	-	-	-	-
	i Geo - Climatic Trials	24.71	99.84	106.11	402.86
	ii Selling and Promotion Expenses	199.70	147.10	278.19	969.43
	iii Other Expenses	158.48	283.58	285.09	1,129.92
	Total Expenses	820.39	2,240.82	1,626.54	6,149.96
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(615.34)	(2,804.27)	235.32	(3,609.63)
4	Other Income	52.97	31.50	7.08	115.75
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	(562.37)	(2,772.77)	242.40	(3,493.88)
6	Finance Cost	111.51	206.34	101.97	498.90
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	(673.88)	(2,979.11)	140.43	(3,992.78)
8	Exceptional Items	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	(673.88)	(2,979.11)	140.43	(3,992.78)
10	Tax Expenses	17.32	(277.60)	62.38	(209.30)
11	Net Profit / (Loss) from Ordinary Activities after tax (9 ± 10)	(691.20)	(2,701.51)	78.05	(3,783.48)
12	Extraordinary Items (net of tax expenses)	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	(691.20)	(2,701.51)	78.05	(3,783.48)
14	Share of Profit / (loss of associates)	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15)	(691.20)	(2,701.51)	78.05	(3,783.48)
17	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,999.98	2,999.98	2,999.98
18	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year	-	-	-	7,423.65
19.i	Earnings per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs				
	(a) Basic	(0.23)	(9.01)	0.26	(12.61)
	(b) diluted	(0.23)	(9.01)	0.26	(12.61)
19.ii	Earnings per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs				
	(a) Basic	(0.23)	(9.01)	0.26	(12.61)
	(b) Diluted	(0.23)	(9.01)	0.26	(12.61)



REPORT OF SEGMENT-WISE STANDALONE REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR QUARTER ENDED AS ON 30TH JUNE 2016

Rupees in Lakhs

Sl. No.	Particulars	Standalone			
		Quarter Ended			Previous Year Ended
		30th June 2016	31st March 2016	30th June 2015	31st March 2016
		(Unaudited)	Refer Note 6	(Unaudited)	Refer Note 6
			Refer Note:4		
1	Segment Revenue				
	a) Seeds and Vegetables	-	-	438.25	-
	b) Agri Biotech Products	205.05	(563.45)	1,423.61	2,540.33
	c) Others	-	-	-	-
	Total	205.05	(563.45)	1,861.86	2,540.33
	Less: Intersegment Revenue	-	-	-	-
	Net Sales/ Income from Operation	205.05	(563.45)	1,861.86	2,540.33
2	Segment Results				
	Profit (+) / Loss (-) before tax and interest from each segment				
	a) Seeds and Vegetables	-	-	195.70	-
	b) Agri Biotech Products	(562.37)	(2,772.78)	238.11	(3,493.88)
	c) Others	-	-	-	-
	Total	(562.37)	(2,772.78)	433.81	(3,493.88)
	Less: (i) Other Net unallocated Income /expenses	-	-	191.40	-
	(ii) Finance Cost	111.51	206.34	101.97	498.90
	Total Profit before Tax	(673.88)	(2,979.12)	140.44	(3,992.78)
3	Segment Assets				
	a) Seeds and Vegetables	-	-	16,474.42	-
	b) Agri Biotech products	16,649.31	16,987.63	14,372.19	16,987.63
	c) Unallocated	-	-	2,952.26	-
	TOTAL	16,649.31	16,987.63	33,798.86	16,987.63
	Segment Liabilities				
	a) Seeds and Vegetables	-	-	2,594.81	-
	b) Agri Biotech products	6,899.55	6,773.29	3,622.16	6,773.29
	c) Unallocated	-	-	1,105.38	-
	TOTAL	6,899.55	6,773.29	7,322.35	6,773.29



Notes :

- 1 The Company has opted to consider the financial results on standalone basis from the 1st quarter of this financial year
- 2 The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 11th August 2016
- 3 The nature of the Company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the Company on quarter to quarter can vary significantly and are therefore not comparable
- 4 During the second quarter the Company received an order dt: 31st July 2015 from the High Court of Karnataka for demerger of Seeds and Vegetables business of the Company with an appointed date of 1st April, 2014. Accordingly the above results have been presented for Agri Biotech business. Consequently the Company operates in a single segment i.e. Agri Biotech and the results relating to previous quarter/period/year are not comparable.

The Profit of the demerged business (i.e. Seeds Business) for the Quarter ended 30th June 2015 was Rs.195.70 lakhs.
- 5 During the previous year, the company has received communication from shareholders to conduct a forensic audit on the financial matters of the Company. The Company's Board of Directors on meeting held on June 11, 2016 has decided the scope of forensic audit and appointed an independent firm for conducting the same. Accordingly, the company is of the view that material adjustments or disclosures, if any, would be considered after conclusion of the forensic audit
- 6 There has been no changes during the period with regard to Auditors remarks on the accounts of 31st March 2016 and the management has responded to the Auditors remarks as mentioned in point 5 above.
- 7 During the Quarter ended 31st March 2016, the Company has provided for sales return amounting to Rs. 414.58 lakhs and Rs. 1,121.28 lakhs towards additional amortisation of certain Intangible Assets.
- 8 Figures for the previous periods/years have been regrouped / rearranged wherever necessary.

Date : August 11, 2016
Place: Bangalore



For and on behalf of the Board of Directors


Veerendra Kumar Singh
Managing Director

A circular purple stamp for Camson Bio Technologies Limited. The outer ring contains the text "Camson Bio Technologies Limited" at the top and "Bangalore" at the bottom, separated by two stars.

INDEPENDENT AUDITOR'S REVIEW REPORT

TO THE BOARD OF DIRECTORS OF CAMSON BIO TECHNOLOGIES LIMITED

1. We were engaged to review the accompanying Statement of Standalone Unaudited Financial Results of **CAMSON BIO TECHNOLOGIES LIMITED** ("the Company") for the quarter ended June 30, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statement is the responsibility of the Company's management and has approved by the Board of directors. The Company's management is required to prepare the said Statement in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Refer Note 5 of the Statement. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Because of the matter described in paragraph 3 below, we were not able to obtain sufficient appropriate evidence to state whether the Statement is free of material misstatement.

3. We draw attention to Note 5 of the Statement. The Company has received communication from shareholders to conduct a forensic audit on the financial matters of the Company. The Company has replied to the said shareholder requesting specific facts and scope/areas for the forensic audit. The Company's Board of Directors has proposed to carry out a forensic audit by appointing an independent committee/legal counsel. As stated in the aforesaid Note, the Company is of the view that material adjustments or disclosures, if any, arising out of the forensic audit would be considered after conclusion of the forensic audit and the Management has not estimated the impact of any adjustment that may arise to the amounts and disclosures in the Statement. Consequently, we have not been able to state whether any adjustments or disclosure would be required to the information included in the Statement and the impact thereof.



4. Because of the significance of the matter described in paragraph 3 above, we do not have a basis to state whether the Statement is prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016), including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Bangalore
Date: August 11, 2016

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
Firm's Registration No. 117366W/W-100018

A handwritten signature in black ink, appearing to read "S. Ganesh".

S. Ganesh
Partner
Membership No. 204108